{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T17:06:47Z","timestamp":1774890407398,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.det.2024.08.001","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T19:33:22Z","timestamp":1725996802000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Innovations in Psoriasis"],"prefix":"10.1016","volume":"43","author":[{"given":"Amylee","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina Kristy","family":"Ibraheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jashin J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2024.08.001_bib1","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.det.2024.08.001_bib2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.jaad.2020.10.035","article-title":"Prevalence of psoriasis among adults in the US 2009-2010 and 2013-2014 national Health and nutrition examination surveys","volume":"84","author":"Liu","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.08.001_bib3","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjd.16083","article-title":"HLA-Cw6 and psoriasis","volume":"178","author":"Chen","year":"2018","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.08.001_bib4","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10.1016\/j.det.2024.08.001_bib5","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.3390\/ijms20133318","article-title":"The significance of IL-36 hyperactivation and IL-36R targeting in psoriasis","volume":"20","author":"Madonna","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.det.2024.08.001_bib6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the pathogenesis of psoriasis: from keratinocyte perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis"},{"issue":"4","key":"10.1016\/j.det.2024.08.001_bib7","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent","volume":"84","author":"Bissonnette","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.det.2024.08.001_bib8","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans","volume":"137","author":"Smith","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"issue":"8","key":"10.1016\/j.det.2024.08.001_bib9","doi-asserted-by":"crossref","first-page":"779","DOI":"10.36849\/jdd.7317","article-title":"Tapinarof, a novel, first-in-class, topical therapeutic aryl hydrocarbon receptor agonist for the management of psoriasis","volume":"22","author":"Bobonich","year":"2023","journal-title":"J\u00a0Drugs Dermatol JDD"},{"issue":"24","key":"10.1016\/j.det.2024.08.001_bib10","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","article-title":"Phase 3 trials of tapinarof cream for plaque psoriasis","volume":"385","author":"Lebwohl","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.det.2024.08.001_bib11","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jaad.2020.04.181","article-title":"A\u00a0phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: secondary efficacy and patient-reported outcomes","volume":"84","author":"Stein","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.08.001_bib12","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2018.10.037","article-title":"Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis","volume":"80","author":"Robbins","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.001_bib13","doi-asserted-by":"crossref","first-page":"22608","DOI":"10.5070\/D3205022608","article-title":"A\u00a0review of phospho-diesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology","volume":"20","author":"Moustafa","year":"2014","journal-title":"Dermatol Online J"},{"issue":"3","key":"10.1016\/j.det.2024.08.001_bib14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2000073","article-title":"Trial of roflumilast cream for chronic plaque psoriasis","volume":"383","author":"Lebwohl","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2024.08.001_bib15","first-page":"21","article-title":"Phosphodiesterase-4 inhibition in psoriasis","volume":"11","author":"Milakovic","year":"2021","journal-title":"Psoriasis Auckl NZ"},{"issue":"4","key":"10.1016\/j.det.2024.08.001_bib16","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","article-title":"Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in\u00a0vitro and in a model of psoriasis","volume":"159","author":"Schafer","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"11","key":"10.1016\/j.det.2024.08.001_bib17","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2022.15632","article-title":"Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials","volume":"328","author":"Lebwohl","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.det.2024.08.001_bib18","doi-asserted-by":"crossref","first-page":"100639","DOI":"10.1016\/j.lanepe.2023.100639","article-title":"Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO)","volume":"30","author":"Gyldenl\u00f8ve","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"10.1016\/j.det.2024.08.001_bib19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40257-022-00741-9","article-title":"Pharmacokinetics of roflumilast cream in chronic plaque psoriasis: data from phase I to phase III studies","volume":"24","author":"Thurston","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"17","key":"10.1016\/j.det.2024.08.001_bib20","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"issue":"14","key":"10.1016\/j.det.2024.08.001_bib21","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.det.2024.08.001_bib22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s13555-021-00649-y","article-title":"Deucravacitinib in moderate to severe psoriasis: clinical and quality-of-life outcomes in a phase 2 trial","volume":"12","author":"Tha\u00e7i","year":"2022","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.det.2024.08.001_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.001_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.001_bib25","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/1346-8138.16740","article-title":"Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial","volume":"50","author":"Imafuku","year":"2023","journal-title":"J\u00a0Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.001_bib26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/1744666X.2023.2195165","article-title":"Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis","volume":"19","author":"Burden","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"issue":"10412","key":"10.1016\/j.det.2024.08.001_bib27","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(23)01378-8","article-title":"Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an\u00a0international, multicentre, randomised, placebo-controlled trial","volume":"402","author":"Morita","year":"2023","journal-title":"Lancet Lond Engl"},{"issue":"4","key":"10.1016\/j.det.2024.08.001_bib28","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jaci.2021.09.035","article-title":"Pustular psoriasis: molecular pathways and effects of spesolimab in generalized pustular psoriasis","volume":"149","author":"Baum","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.det.2024.08.001_bib29","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMc1811317","article-title":"Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis","volume":"380","author":"Bachelez","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.det.2024.08.001_bib30","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of spesolimab for generalized pustular psoriasis","volume":"385","author":"Bachelez","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.det.2024.08.001_bib31","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/jdv.18820","article-title":"Spesolimab improves patient-reported outcomes in patients with generalized pustular psoriasis: results from the Effisayil 1 study","volume":"37","author":"Navarini","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol JEADV"},{"issue":"1","key":"10.1016\/j.det.2024.08.001_bib32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jaad.2023.02.040","article-title":"Rapid and sustained improvements in generalized pustular psoriasis physician global assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study","volume":"89","author":"Elewski","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2024.08.001_bib33","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/exd.14824","article-title":"Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study","volume":"32","author":"Burden","year":"2023","journal-title":"Exp Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.08.001_bib34","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13555-021-00504-0","article-title":"Spesolimab, an anti-interleukin-36 receptor antibody, in patients with palmoplantar pustulosis: results of a phase IIa, multicenter, double-blind, randomized, placebo-controlled pilot study","volume":"11","author":"Mrowietz","year":"2021","journal-title":"Dermatol Ther"},{"issue":"12","key":"10.1016\/j.det.2024.08.001_bib35","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s40262-022-01176-5","article-title":"Assessment of the pharmacokinetics and safety of spesolimab, a humanised anti-interleukin-36 receptor monoclonal antibody, in healthy non-Japanese and Japanese subjects: results from phase I clinical studies","volume":"61","author":"Joseph","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"10.1016\/j.det.2024.08.001_bib36","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s13555-022-00760-8","article-title":"Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol Ther"},{"issue":"7","key":"10.1016\/j.det.2024.08.001_bib37","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/03007995.2023.2228613","article-title":"Meta-analysis and GRADE assessment of randomized controlled trials on the efficacy and safety of bimekizumab in psoriatic arthritis patients","volume":"39","author":"Mahmoud","year":"2023","journal-title":"Curr Med Res Opin"},{"issue":"10370","key":"10.1016\/j.det.2024.08.001_bib38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet Lond Engl"},{"issue":"10370","key":"10.1016\/j.det.2024.08.001_bib39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet Lond Engl"},{"issue":"7","key":"10.1016\/j.det.2024.08.001_bib40","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamadermatol.2022.1185","article-title":"Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase 2 and phase 3 randomized clinical trials","volume":"158","author":"Gordon","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.001_bib41","doi-asserted-by":"crossref","first-page":"2199106","DOI":"10.1080\/09546634.2023.2199106","article-title":"Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trials","volume":"34","author":"Qiu","year":"2023","journal-title":"J\u00a0Dermatol Treat"},{"issue":"4","key":"10.1016\/j.det.2024.08.001_bib42","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/jdv.18812","article-title":"Oral orismilast: efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets","volume":"37","author":"Warren","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol JEADV"},{"issue":"4","key":"10.1016\/j.det.2024.08.001_bib43","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/jdv.18818","article-title":"Pharmacology of orismilast, a potent and selective PDE4 inhibitor","volume":"37","author":"Silverberg","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol JEADV"},{"issue":"7","key":"10.1016\/j.det.2024.08.001_bib44","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/13543784.2023.2242767","article-title":"Psoriasis: a focus on upcoming oral formulations","volume":"32","author":"Rusi\u00f1ol","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.det.2024.08.001_bib45","article-title":"Orismilast in moderate-to-severe psoriasis: efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)","author":"Warren","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1_suppl","key":"10.1016\/j.det.2024.08.001_bib46","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1177\/12034754221141680","article-title":"Clinical implications of targeting the JAK-STAT pathway in psoriatic disease: emphasis on the TYK2 pathway","volume":"27","author":"Loo","year":"2023","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.det.2024.08.001_bib47","doi-asserted-by":"crossref","first-page":"110434","DOI":"10.1016\/j.intimp.2023.110434","article-title":"Recent progress on tyrosine kinase 2 JH2 inhibitors","volume":"121","author":"Deng","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.det.2024.08.001_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1186455","article-title":"Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies","volume":"14","author":"Brembilla","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.det.2024.08.001_bib50","series-title":"DICE therapeutics announces positive topline data from phase 1 clinical trial of lead oral IL-17 antagonist, DC-806, for psoriasis","author":"Inc","year":"2022"},{"key":"10.1016\/j.det.2024.08.001_bib51","doi-asserted-by":"crossref","unstructured":"Bissonnette R, Pinter A, Ferris L, et al. Data Presentation. A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER 1. Presented at WCD 2023, July 3\u20138. Suntec Singapore Convention & Exhibition Centre; Singapore and Pan Pacific Singapore.","DOI":"10.1016\/j.jid.2023.09.086"},{"key":"10.1016\/j.det.2024.08.001_bib52","unstructured":"Janssen announces positive topline results for JNJ-2113 - a novel, first and only oral IL-23 receptor antagonist peptide in development for moderate-to-severe plaque psoriasis. Content Lab (U.S). 2023. Available at: https:\/\/www.jnj.com\/media-center\/press-releases\/janssen-announces-positive-topline-results-for-jnj-2113-a-novel-first-and-only-oral-il-23-receptor-antagonist-peptide-in-development-for-moderate-to-severe-plaque-psoriasis#:\u223c:text=SPRING%20HOUSE%2C%20PENNSYLVANIA%2C%20July%204,in%20adult%20patients%20with%20moderate. (Accessed January 3 2024)."},{"key":"10.1016\/j.det.2024.08.001_bib53","author":"Deren-Lewis"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T13:04:07Z","timestamp":1755695047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524000731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0733863524000731"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.08.001","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovations in Psoriasis","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}